Karyopharm Therapeutics | KPTI - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 5.23B 400M 2025-12
Abbott USD 8.52B 1.01B 2025-12
Amgen USD 9.13B 316M 2025-12
AstraZeneca USD 8.14B 1.08B 2025-09
BioCryst Pharmaceuticals USD 335.91M 251.83M 2025-12
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Eli Lilly USD 7.27B 2.52B 2025-12
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
GlaxoSmithKline GBP 3.3B 303M 2025-09
Incyte USD 3.58B 650.78M 2025-12
J&J USD 19.71B 1.48B 2025-12
Karyopharm Therapeutics USD 37.67M 1.05M 2025-09
MacroGenics USD 57.22M 22.91M 2025-12
Merck USD 18.17B 10.16B 2025-09
Nektar Therapeutics USD 41.03M 1.96M 2025-09
Novartis USD 9.56B 2.9B 2025-09
Novartis USD 9.56B 2.9B 2025-09
Pfizer USD 1.34B 295M 2025-09
Regeneron Pharmaceuticals USD 18.87B 16.36B 2025-12
Roche Holding CHF 7.55B 579M 2025-06
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Takeda JPY 654.94B 26.55B 2025-12
Tectonic Therapeutic USD 253.8M 14.64M 2025-12
TG Therapeutics USD 199.51M 21.2M 2025-12
Ultragenyx Pharmaceutical USD 202.51M 36.4M 2025-09
Xencor USD 54.07M 25.78M 2025-12